热门资讯> 正文
Kiniksa Pharmaceuticals报告第一季度业绩好坏参半;上调24财年前景
2024-04-23 19:37
- Kiniksa Pharmaceuticals, Ltd.(KNSA) 0
- BlackRock ETF Trust II BlackRock Short-Term California Muni Bond ETF(CALY) 0
- Kiniksa Pharmaceuticals press release (NASDAQ:KNSA): Q1 GAAP EPS of -$0.25 misses by $0.09.
- Revenue of $79.86M (+65.2% Y/Y) beats by $1.4M.
- As of March 31, 2024, Kiniksa had $213.6 million of cash, cash equivalents, and short-term investments and no debt.
- Financial Guidance
- Kiniksa expects 2024 ARCALYST net product revenue of between $370 million and $390 million, compared to prior guidance of between $360 million and $380 million.
- Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.
More on Kiniksa Pharmaceuticals
- Seeking Alpha’s Quant Rating on Kiniksa Pharmaceuticals
- Historical earnings data for Kiniksa Pharmaceuticals
- Financial information for Kiniksa Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
